Switch to:
Also traded in: Germany, South Africa

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.19
OTCPK:APNHF's Cash-to-Debt is ranked lower than
86% of the 859 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.03 vs. OTCPK:APNHF: 0.19 )
Ranked among companies with meaningful Cash-to-Debt only.
OTCPK:APNHF' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.19  Med: 0.34 Max: 128.44
Current: 0.19
0.19
128.44
Equity-to-Asset 0.38
OTCPK:APNHF's Equity-to-Asset is ranked lower than
82% of the 788 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. OTCPK:APNHF: 0.38 )
Ranked among companies with meaningful Equity-to-Asset only.
OTCPK:APNHF' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.3  Med: 0.39 Max: 0.55
Current: 0.38
0.3
0.55
Debt-to-Equity 1.16
OTCPK:APNHF's Debt-to-Equity is ranked lower than
87% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.32 vs. OTCPK:APNHF: 1.16 )
Ranked among companies with meaningful Debt-to-Equity only.
OTCPK:APNHF' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01  Med: 0.73 Max: 1.55
Current: 1.16
0.01
1.55
Debt-to-EBITDA 5.98
OTCPK:APNHF's Debt-to-EBITDA is ranked lower than
81% of the 495 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.92 vs. OTCPK:APNHF: 5.98 )
Ranked among companies with meaningful Debt-to-EBITDA only.
OTCPK:APNHF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 2.14  Med: 3.64 Max: 5.98
Current: 5.98
2.14
5.98
Interest Coverage 4.61
OTCPK:APNHF's Interest Coverage is ranked lower than
83% of the 648 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 86.08 vs. OTCPK:APNHF: 4.61 )
Ranked among companies with meaningful Interest Coverage only.
OTCPK:APNHF' s Interest Coverage Range Over the Past 10 Years
Min: 3.11  Med: 4.86 Max: 5.98
Current: 4.61
3.11
5.98
Piotroski F-Score: 6
Altman Z-Score: 1.52
Beneish M-Score: -2.44
WACC vs ROIC
10.63%
9.75%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 24.82
OTCPK:APNHF's Operating Margin % is ranked higher than
82% of the 801 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.97 vs. OTCPK:APNHF: 24.82 )
Ranked among companies with meaningful Operating Margin % only.
OTCPK:APNHF' s Operating Margin % Range Over the Past 10 Years
Min: 23.27  Med: 25.6 Max: 28.65
Current: 24.82
23.27
28.65
Net Margin % 14.11
OTCPK:APNHF's Net Margin % is ranked higher than
76% of the 802 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.32 vs. OTCPK:APNHF: 14.11 )
Ranked among companies with meaningful Net Margin % only.
OTCPK:APNHF' s Net Margin % Range Over the Past 10 Years
Min: 12.08  Med: 16.51 Max: 20.82
Current: 14.11
12.08
20.82
ROE % 13.11
OTCPK:APNHF's ROE % is ranked higher than
75% of the 832 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.94 vs. OTCPK:APNHF: 13.11 )
Ranked among companies with meaningful ROE % only.
OTCPK:APNHF' s ROE % Range Over the Past 10 Years
Min: 11.23  Med: 17.97 Max: 36.01
Current: 13.11
11.23
36.01
ROA % 4.85
OTCPK:APNHF's ROA % is ranked higher than
61% of the 871 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.88 vs. OTCPK:APNHF: 4.85 )
Ranked among companies with meaningful ROA % only.
OTCPK:APNHF' s ROA % Range Over the Past 10 Years
Min: 4.46  Med: 8.48 Max: 12.24
Current: 4.85
4.46
12.24
ROC (Joel Greenblatt) % 45.45
OTCPK:APNHF's ROC (Joel Greenblatt) % is ranked higher than
88% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.23 vs. OTCPK:APNHF: 45.45 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OTCPK:APNHF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 32.99  Med: 49.85 Max: 79.26
Current: 45.45
32.99
79.26
3-Year Revenue Growth Rate 5.70
OTCPK:APNHF's 3-Year Revenue Growth Rate is ranked higher than
70% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. OTCPK:APNHF: 5.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
OTCPK:APNHF' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 5.7  Med: 22.6 Max: 33.4
Current: 5.7
5.7
33.4
3-Year EBITDA Growth Rate 3.30
OTCPK:APNHF's 3-Year EBITDA Growth Rate is ranked lower than
57% of the 704 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. OTCPK:APNHF: 3.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
OTCPK:APNHF' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 2  Med: 24.1 Max: 46.5
Current: 3.3
2
46.5
3-Year EPS without NRI Growth Rate 4.90
OTCPK:APNHF's 3-Year EPS without NRI Growth Rate is ranked lower than
62% of the 663 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. OTCPK:APNHF: 4.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OTCPK:APNHF' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0.8  Med: 26 Max: 365.5
Current: 4.9
0.8
365.5
GuruFocus has detected 4 Warning Signs with Aspen Pharmacare Holdings Ltd OTCPK:APNHF.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OTCPK:APNHF's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with APNHF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic  
Compare:SZSE:300122, XSWX:VIFN, SZSE:000963, TSE:4508, SHSE:600332, HKSE:03320, NYSE:PRGO, OCSE:LUN, SHSE:600085, TSE:4581, SHSE:600535, TSE:4506, SZSE:002001, TSE:4530, SHSE:600566, TSX:VRX, BOM:532321, SZSE:002773, SZSE:000423, HKSE:00867 » details
Traded in other countries:LDZA.Germany, APN.South Africa,
Headquarter Location:South africa
Aspen Pharmacare Holdings Ltd through its subsidiaries, is engaged in manufacturing, marketing and distribution of branded and generic pharmaceutical, as well as nutritional products in Australasia, China, Japan and other Asia.

Aspen Pharmacare Holdings Ltd is a specialty and generic drug manufacturing company. The company maintains a focus on four therapeutic categories: thrombosis, anaesthetics, high potency and cytotoxics, and infant nutritionals. Aspen generates the vast majority of its revenue through its commercial-pharma segment, followed by manufacturing and commercial-nutritionals segments. The company considers potential merger and acquisition investment a component of its operational growth strategy to expand its research, development, manufacturing, and marketing capabilities.

Ratios

vs
industry
vs
history
PE Ratio 10.63
APNHF's PE Ratio is ranked higher than
65% of the 557 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.77 vs. APNHF: 10.63 )
Ranked among companies with meaningful PE Ratio only.
APNHF' s PE Ratio Range Over the Past 10 Years
Min: 9.84  Med: 23.56 Max: 40.2
Current: 10.63
9.84
40.2
PE Ratio without NRI 10.63
APNHF's PE Ratio without NRI is ranked higher than
66% of the 556 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.20 vs. APNHF: 10.63 )
Ranked among companies with meaningful PE Ratio without NRI only.
APNHF' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.84  Med: 24.49 Max: 40.2
Current: 10.63
9.84
40.2
Price-to-Owner-Earnings 16.78
APNHF's Price-to-Owner-Earnings is ranked lower than
59% of the 324 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 31.95 vs. APNHF: 16.78 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
APNHF' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 15.52  Med: 46.69 Max: 132.77
Current: 16.78
15.52
132.77
PB Ratio 1.28
APNHF's PB Ratio is ranked higher than
50% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.64 vs. APNHF: 1.28 )
Ranked among companies with meaningful PB Ratio only.
APNHF' s PB Ratio Range Over the Past 10 Years
Min: 1.18  Med: 4.01 Max: 7.5
Current: 1.28
1.18
7.5
PS Ratio 1.50
APNHF's PS Ratio is ranked higher than
52% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. APNHF: 1.50 )
Ranked among companies with meaningful PS Ratio only.
APNHF' s PS Ratio Range Over the Past 10 Years
Min: 1.39  Med: 3.7 Max: 6.78
Current: 1.5
1.39
6.78
Price-to-Operating-Cash-Flow 9.11
APNHF's Price-to-Operating-Cash-Flow is ranked higher than
60% of the 392 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 22.00 vs. APNHF: 9.11 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
APNHF' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.42  Med: 23.13 Max: 54.21
Current: 9.11
8.42
54.21
EV-to-EBIT 11.42
APNHF's EV-to-EBIT is ranked higher than
52% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.85 vs. APNHF: 11.42 )
Ranked among companies with meaningful EV-to-EBIT only.
APNHF' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.4  Med: 18.6 Max: 29.5
Current: 11.42
9.4
29.5
EV-to-EBITDA 11.42
APNHF's EV-to-EBITDA is ranked lower than
56% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.24 vs. APNHF: 11.42 )
Ranked among companies with meaningful EV-to-EBITDA only.
APNHF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.3  Med: 17.2 Max: 26.7
Current: 11.42
8.3
26.7
EV-to-Revenue 2.60
APNHF's EV-to-Revenue is ranked lower than
54% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.24 vs. APNHF: 2.60 )
Ranked among companies with meaningful EV-to-Revenue only.
APNHF' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.5  Med: 4.4 Max: 7.8
Current: 2.6
2.5
7.8
PEG Ratio 1.00
APNHF's PEG Ratio is ranked higher than
67% of the 317 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.93 vs. APNHF: 1.00 )
Ranked among companies with meaningful PEG Ratio only.
APNHF' s PEG Ratio Range Over the Past 10 Years
Min: 0.37  Med: 1.08 Max: 2.09
Current: 1
0.37
2.09
Shiller PE Ratio 15.73
APNHF's Shiller PE Ratio is ranked lower than
51% of the 252 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.75 vs. APNHF: 15.73 )
Ranked among companies with meaningful Shiller PE Ratio only.
APNHF' s Shiller PE Ratio Range Over the Past 10 Years
Min: 14.5  Med: 52.11 Max: 90.66
Current: 15.73
14.5
90.66
Current Ratio 1.43
APNHF's Current Ratio is ranked lower than
90% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. APNHF: 1.43 )
Ranked among companies with meaningful Current Ratio only.
APNHF' s Current Ratio Range Over the Past 10 Years
Min: 0.7  Med: 1.32 Max: 1.95
Current: 1.43
0.7
1.95
Quick Ratio 0.91
APNHF's Quick Ratio is ranked lower than
92% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.87 vs. APNHF: 0.91 )
Ranked among companies with meaningful Quick Ratio only.
APNHF' s Quick Ratio Range Over the Past 10 Years
Min: 0.49  Med: 0.94 Max: 1.31
Current: 0.91
0.49
1.31
Days Inventory 241.31
APNHF's Days Inventory is ranked lower than
85% of the 755 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 119.80 vs. APNHF: 241.31 )
Ranked among companies with meaningful Days Inventory only.
APNHF' s Days Inventory Range Over the Past 10 Years
Min: 115.22  Med: 150.76 Max: 259.83
Current: 241.31
115.22
259.83
Days Sales Outstanding 92.86
APNHF's Days Sales Outstanding is ranked lower than
74% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 81.76 vs. APNHF: 92.86 )
Ranked among companies with meaningful Days Sales Outstanding only.
APNHF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 79.88  Med: 92.21 Max: 106.95
Current: 92.86
79.88
106.95
Days Payable 77.88
APNHF's Days Payable is ranked higher than
80% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 76.32 vs. APNHF: 77.88 )
Ranked among companies with meaningful Days Payable only.
APNHF' s Days Payable Range Over the Past 10 Years
Min: 72.18  Med: 118 Max: 152.63
Current: 77.88
72.18
152.63

Buy Back

vs
industry
vs
history
3-Year Dividend Growth Rate 15.10
APNHF's 3-Year Dividend Growth Rate is ranked higher than
73% of the 299 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.40 vs. APNHF: 15.10 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
APNHF' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 15.1 Max: 63.4
Current: 15.1
0
63.4

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.12
APNHF's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
99.99% of the 374 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.11 vs. APNHF: 1.12 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
APNHF' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.12  Med: 3.61 Max: 5.84
Current: 1.12
1.12
5.84
Price-to-Intrinsic-Value-DCF (Earnings Based) 0.43
APNHF's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
86% of the 110 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.36 vs. APNHF: 0.43 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
APNHF' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.79  Med: 1 Max: 1.35
Current: 0.43
0.79
1.35
Price-to-Median-PS-Value 0.41
APNHF's Price-to-Median-PS-Value is ranked lower than
99.99% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.94 vs. APNHF: 0.41 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
APNHF' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.4  Med: 0.89 Max: 1.45
Current: 0.41
0.4
1.45
Price-to-Peter-Lynch-Fair-Value 1.00
APNHF's Price-to-Peter-Lynch-Fair-Value is ranked lower than
99.99% of the 212 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.41 vs. APNHF: 1.00 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
APNHF' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.54  Med: 1.25 Max: 1.85
Current: 1
0.54
1.85
Earnings Yield (Greenblatt) % 8.76
APNHF's Earnings Yield (Greenblatt) % is ranked higher than
69% of the 867 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.31 vs. APNHF: 8.76 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
APNHF' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.4  Med: 5.4 Max: 10.6
Current: 8.76
3.4
10.6
Forward Rate of Return (Yacktman) % 12.40
APNHF's Forward Rate of Return (Yacktman) % is ranked higher than
77% of the 421 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.96 vs. APNHF: 12.40 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
APNHF' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 11.5  Med: 20 Max: 22
Current: 12.4
11.5
22

More Statistics

Revenue (TTM) (Mil) $3,227.28
EPS (TTM) $ 1.00
Beta1.41
Volatility46.07%
52-Week Range $8.74 - 22.73
Shares Outstanding (Mil)455.97

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

» More Articles for APNHF

Headlines

Articles On GuruFocus.com
Jono Nov 06 2018 
Mylan and Aspen Announce Launch of Generic Busulfex® Injection Dec 04 2017 

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}